Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 101 to 110 of 334

TitleReference numberPublishedLast updated
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancerHTG659
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatmentsTA862
Thyroid cancer: assessment and managementNG230
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancerHTG642
Signatera for detecting molecular residual disease from solid tumour cancersMIB307

Results per page

  1. 10
  2. 25
  3. 50
  4. All